Clinical trials: Placebo-Pre
Non-small Cell Lung Cancer Metastatic
A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line…
- Trial name
- NCT01703091
- Testing
- Ramucirumab, Docetaxel
- Where
- 15 sites in Japan
- Volunteers
- 197 people
- Sponsor
- Eli Lilly and Company
Pre-eclampsia
Efficacy Study of Digibind for Treatment of Severe Preeclampsia
The purpose of this study is to determine whether a commercially available anti-digoxin antibody, Digibind, can delay delivery in patients with severe pre-eclampsia.
- Trial name
- NCT00158743
- Testing
- Anti-digoxin antibody (FAB fragment), sodium chloride
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- BTG International Inc.
Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe…
- Trial name
- ELENA (NCT05560646)
- Testing
- OG-6219
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 354 people
- Sponsor
- Organon and Co
Bowel Preparation for Colonoscopy
Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy
The primary outcomes of this procedure will be: 1. The cleanliness of the prep as measured by the Ottawa Scale (attachment a). Secondary outcomes will be: 1.
- Trial name
- NCT00611442
- Testing
- lubiprostone
- Where
- United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Brooke Army Medical Center
Uterine Fibroids, Anemia
Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids
Eligible female subjects will be randomly assigned to one of the three treatment groups. Subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily during study drug treatment.
- Trial name
- NCT00702702
- Testing
- Proellex 25 mg, Proellex 50 mg
- Where
- 30 sites in United States
- Volunteers
- 56 people
- Sponsor
- Repros Therapeutics Inc.
Pre Diabetes, Polycystic Ovary Syndrome
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS).
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Trial name
- SAXAPCOS (NCT03480022)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Woman's
Herpes Zoster
Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
The purpose of this study was to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who had a previous episode of Herpes Zoster (HZ).
- Trial name
- NCT04091451
- Testing
- Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)
- Where
- 3 sites in Russia
- Volunteers
- 1,430 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Prostate Cancer
Study of Immunotherapy to Treat Advanced Prostate Cancer
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
- Trial name
- NCT00861614
- Testing
- Ipilimumab
- Where
- 158 sites in United States, Argentina and 25 more
- Volunteers
- 988 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer, Lung Cancer
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell…
- Trial name
- NCT00745875
- Testing
- ZD4054, Pemetrexed
- Where
- 13 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 66 people
- Sponsor
- AstraZeneca
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Fever
Acetaminophen Before Vaccines for Infants Study (AVIS)
The purpose of this study is to see whether giving acetaminophen (the medicine in Tylenol) for routine infant vaccinations is helpful in preventing fever or other symptoms.
- Trial name
- NCT00325819
- Testing
- Acetaminophen
- Where
- United States
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Hepatocellular Carcinoma
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.
- Trial name
- CELESTIAL (NCT01908426)
- Testing
- Cabozantinib tablets
- Where
- 104 sites in United States, Australia and 17 more
- Volunteers
- 707 people
- Sponsor
- Exelixis
Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma
Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
This randomized phase II trial studies how well regorafenib works in treating patients with cancer of the esophagus or gastroesophageal junction that has spread from where it started to nearby tissue or lymph nodes and have…
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma
- Trial name
- NCT02234180
- Testing
- Regorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Body Weight, Non-restrained Eaters
Appetite Suppression Trial With Polydextrose
Overweight and obesity are a global epidemic, which causes a rapid increase in the frequency of diabetes and cardiovascular diseases.
- Trial name
- NCT02064205
- Testing
- 12.5 g polydextrose, glucose syrup
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- W.J. Pasman
Hepatocellular Carcinoma
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01210495
- Testing
- Axitinib (AG-013736), Best Supportive Care
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 224 people
- Sponsor
- Pfizer
Respiratory Syncytial Viruses, Lower Respiratory Tract Disease
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
The study will enroll up to 27,200 participants in order to demonstrate the efficacy of the active Ad26.RSV.preF-based study vaccine in the prevention of Reverse Transcription Polymerase Chain Reaction (RT-PCR) confirmed…
- Trial name
- EVERGREEN (NCT04908683)
- Testing
- Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF
- Where
- 272 sites in United States, Australia and 12 more
- Volunteers
- 25,236 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Irritable Bowel Syndrome With Diarrhea
Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of…
- Trial name
- NCT02959983
- Testing
- Eluxadoline
- Where
- 83 sites in United States, Canada
- Volunteers
- 346 people
- Sponsor
- Allergan
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation
Primary Objectives: Part 1: To determine the safety and tolerability of 4, 8, and 15 milligrams of GZ/SAR402671 (venglustat) administered orally for 4 weeks, as compared to placebo in participants with early-stage Parkinson's…
- Trial name
- MOVES-PD (NCT02906020)
- Testing
- venglustat GZ/SAR402671
- Where
- 52 sites in United States, Austria and 14 more
- Volunteers
- 273 people
- Sponsor
- Genzyme, a Sanofi Company
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
This Phase II, double-blind, randomized, placebo-controlled multicenter study will investigate the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or atezolizumab-placebo in participants with…
- Trial name
- KATE2 (NCT02924883)
- Testing
- Atezolizumab, Trastuzumab emtansine
- Where
- 68 sites in United States, Australia and 7 more
- Volunteers
- 202 people
- Sponsor
- Hoffmann-La Roche